Prehistoric humans may have used fire to smoke meat one million years ago, study suggests
A groundbreaking study by researchers at Tel Aviv University suggests that early humans may have started using fire for a surprising reason: to smoke and preserve meat. According to the study, which was published in Frontiers in Nutrition, this practice could date back as far as one million years.
The research, led by Dr. Miki Ben-Dor and Professor Ran Barkai of the university's Department of Archaeology and Ancient Near Eastern Cultures, challenges the long-held assumption that early humans initially used fire primarily for cooking. Instead, the researchers argue that fire served two essential purposes for our ancient ancestors: first, to protect large game from predators and scavengers, and second, to prevent meat from spoiling by smoking and drying it, thus extending its shelf life.
'Fire was a precious resource for early humans, requiring significant effort to gather fuel, ignite, and maintain,' said Dr. Ben-Dor. 'They wouldn't have invested that effort without a strong, energy-efficient reason. Smoking meat was a way to preserve their most important source of calories.'
The study focuses on sites dating from 1.8 million to 800,000 years ago, where evidence of fire use has been found. Researchers reviewed nine such sites worldwide, including two in Israel - Gesher Benot Ya'aqov and Evron Quarry -six in Africa, and one in Spain. Intriguingly, all of these sites also contained the remains of large animals such as elephants, hippos, and rhinoceroses, creatures that would have provided a rich and vital source of nutrition for early humans.
'The meat and fat from a single elephant could feed a group of 20 to 30 people for over a month,' explained Prof. Barkai. 'That's an enormous amount of food that needed protection not just from other predators, but also from spoilage.'
The study fits into a larger theory developed by Ben-Dor and Barkai that connects many prehistoric phenomena, such as tool use and hunting strategies, to early humans' reliance on large animals for survival. Over time, as the availability of large game declined, humans had to adapt to hunting smaller animals and using fire more consistently.
'Once fire was used to protect and preserve meat, it likely also provided opportunities to cook meat,' Barkai added. 'Cooking could have emerged as a byproduct of this initial use, at no extra energetic cost.'
The findings provide a fresh perspective on a question that has long fascinated archaeologists: why did early humans first harness fire? The answer, according to this new research, may lie in the simple need to make the most of a hard-won meal.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Politico
an hour ago
- Politico
How the Energy secretary picked a fight with climate science
The Department of Energy isn't traditionally the federal government's vanguard for grand debates about climate research. But Energy Secretary Chris Wright is trying to change that — in a bid to shore up President Donald Trump's rollback of climate regulations. The most striking result to date is a DOE report issued last month that questions the traditional underpinnings of climate science. The report, inked by a tag team of climate contrarians handpicked by the secretary, came out on the same day that the Environmental Protection Agency announced it would overturn the Obama-era legal doctrine that undergirds most federal climate rules. Wright, a former fracking services executive who also serves as second-in-command of the White House's National Energy Dominance Council, personally gathered the researchers for his climate-questioning squad just weeks into the job, writes my colleague Benjamin Storrow. They included Roy Spencer, a former NASA scientist; Judith Curry, a climatologist and retired professor at the Georgia Institute of Technology; John Christy, an atmospheric scientist at the University of Alabama in Huntsville; Steven Koonin, a former chief scientist for BP who also served as an undersecretary at the Energy Department during the Obama administration; and Canadian environmental economist Ross McKitrick. Each researcher has publicly questioned some of the broader findings accepted by the world's climate scientists, including numerous previously published federal reports. And several have worked to downplay the risks of fossil-fuel-driven climate change. Those proved strong credentials for Wright, who has long preached that fossil fuels can solve global energy poverty. He's accused mainstream scientists, and the media, of overhyping the risks of a planet rapidly heating up. Carbon dioxide is a 'life-giving plant food,' Wright said in a podcast earlier this month with Wall Street Journal columnist Kim Strassel. 'It does absorb infrared radiation so we can have a real dialogue about too much of it or too little of it … but calling it a pollutant is just nuts,' he said. (Note: Other kinds of 'plant food' — for example, nitrogen and phosphorus — are also pollutants when found in excessive quantities.) By May, Wright's team had compiled a 141-page report questioning the veracity of climate models, the threat of sea-level rise and the connection between burning fossil fuels and extreme weather, Ben writes. It withheld the report's release until last month to coincide with EPA's proposal to reverse the 'endangerment finding,' its 2009 legal conclusion that greenhouse gases are a harmful pollutant that the agency must regulate. The administration hasn't yet spelled out how widely it will deploy the DOE report in its coming legal and regulatory battles over Trump's efforts to smooth the path for fossil fuels — although the EPA proposal cited the report 16 times, Ben notes. But if the study was meant to disrupt mainstream science — or spawn what Strassel has hailed as a 'healthy, vigorous debate' over the research — it doesn't seem to have done that. Instead, other academics and scientists in the field have accused the team of cherry-picking or misrepresenting past research to support its favored conclusion. Andrew Dessler, a climate scientist at Texas A&M University, panned the study on the social media site X as 'a law brief from attorneys defending their client, carbon dioxide.' It's Monday — thank you for tuning in to POLITICO's Power Switch. I'm your host, Heather Richards. Power Switch is brought to you by the journalists behind E&E News and POLITICO Energy. Send your tips, comments, questions to hrichards@ Today in POLITICO Energy's podcast: Kelsey Tamborrino and Alex Guillén break down the Trump administration's latest attacks on wind and solar power. Power Centers Interior gets 'hostile' on windTrump's escalating moves against wind energy have alarmed advocates of renewable energy and free markets, Ian M. Stevenson writes. Since mid-July, the Interior Department has halted spending on projects and required high-level signoff for any action on renewables. Administration officials have said renewable power is an unreliable source of electricity, and Trump has often targeted 'windmills' during attacks on former President Joe Biden's energy policy. 'It's a hostile way to kill and bottleneck these projects,' Ashna Aggarwal, director of analysis at the research firm Greenline Insights, told Ian. 'Targeting wind specifically seems to be an agenda of this administration.' Trump 2.0's first FERC chair exitsMark Christie came in as chair of the Federal Energy Regulatory Commission in lockstep with Trump's vision of energy dominance, even if he was at odds with the White House on executive power in his tenure that ended Friday, Francisco 'A.J.' Camacho writes. He stepped in, for example, to write letters on behalf of FERC staff when the Trump administration asked federal workers to justify their jobs. 'He's no shrinking violet,' Albert Pollard, a former state lawmaker in Virginia, said of Christie. The exit of Republican Christie leaves FERC with a 2-1 Democratic majority. POLITICO on Friday reported that Trump plans to elevate Democratic Commissioner David Rosner to chair. If Rosner gets the nod, he could be temporary. The White House is waiting for Senate confirmation of two Republican commissioners. Either one could be named chair by Trump. The AI race gets politicalThe push by companies like OpenAI and Google to win the artificial intelligence race has led to a proliferation of energy-hungry data centers across the country. The rise of these server farms has sparked fierce battles from Virginia to Arizona and beyond. City and county governments are grappling with how to balance new jobs and new revenue streams against the strain data centers put on water and energy resources, Jordan Wolman and Lisa Kashinsky report. The surge is proving polarizing, particularly in northern Virginia — considered the tip of the spear on this issue with the world's largest and fastest-growing data center market. And across the U.S., the debate is inching up the ballot as state lawmakers race to regulate and governors rush to embrace a new economic boon. In Other News Cleaner power: A microgrid run on lithium-ion batteries and liquid hydrogen has replaced diesel backup generators in a California town that frequently lost power because of wildfires. Reuse: Aluminum recycling is a faster and less energy-intensive way for U.S. companies to get around a 50 percent tariff on imports, metals executives and analysts say. Subscriber Zone A showcase of some of our best subscriber content. Artificial intelligence could need electricity equal to half of the nation's nuclear power fleet by 2030, according to a new analysis. The majority owner of the coal-fired Four Corners power plant in New Mexico plans to extend its use rather than retire it in 2031 to help avert an electricity reliability crunch in the West. Republicans in Congress are again looking to place a federal fee on electric vehicles to boost the Highway Trust Fund. One person is dead, another is unaccounted for and at least 10 are injured following an explosion at a U.S. Steel plant near Pittsburgh. That's it for today, folks! Thanks for reading.


Tom's Guide
8 hours ago
- Tom's Guide
I always put a coin in my freezer before I go on vacation — here's why
I once got back from a vacation to a freezer that felt... slightly off. My ice cream had crystallized, my frozen prawns were stuck together flat at the bottom of the drawer, and my chicken had freezer burn. Although I couldn't say for sure this was the result of a power cut, I felt it was safer to throw out the entire contents of the freezer. It was an expensive day. Even now, I've got no idea whether that was a necessary precaution to take, or a total waste of food and money. But I've discovered a simple hack that gives me some major peace of mind before I go away, and I've never looked back. It involves two things: a cup full of frozen water and a coin. Here's how it works. Here's how the coin hack works. You freeze some water overnight (I use a ramekin dish to do this) and then place a coin flat on top of it. Last time I came back from vacation, my coin was still laying flat on top of my ice. That means my block of ice never melted, therefore my freezer was working throughout my trip, and my precious frozen meals are almost certainly still safe to eat. If you come back from vacation and the coin is now frozen inside the ice, as opposed to sitting on top of it, that means your freezer has defrosted while you were away, and your ice has re-frozen around the coin after it melted. The hack reminds me of my traumatic freezer incident of 2023. I could maybe have overlooked the prawns being slightly too flat, and freezer burn can happen even if your freezer hasn't stopped working, but the cookie dough pieces in my beloved Ben & Jerry's ice cream had sadly sunk to the bottom of the pint. That would never have happened unless the freezer was broken for long enough for the ice cream to fully defrost. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. So while the coin hack isn't a perfect system — you can't tell how long your freezer was defrosted for, or what caused it — it's a super cheap and last-minute trick that will work in a pinch if you're about to go on vacation. This WiFi refrigerator thermometer offers a smarter way of identifying when your refrigerator isn't functioning properly. Get instant app notifications, email alerts, and buzzer alarms when temperatures exceed your preset range. I don't have any trouble keeping my freezer full. I'm currently testing the Ninja Creami Swirl, and it's full of pint containers ready to be turned into delicious soft-serve. But if you're about to head on vacation, it could be a good idea to fill up your freezer. 'It might be surprising, but a full freezer is actually more efficient to run," says Matthew Glynn, Senior Product Manager at Hisense. "The appliance doesn't need to work as hard to supply freezing air. Therefore, if your freezer is only half full, consider using bottles of water to fill the space so that you save on energy costs.' 'If you're heading off for a longer trip of two weeks or more, it may be wise to consider how your fridge will be running in your absence," says Glynn. "Depending on what food you have left and the use-by dates, you should consider either switching to a dedicated holiday mode or turning the temperature to a slightly warmer setting to use less energy and ultimately save on running costs. This helps to reduce energy consumption and avoid returning to any unpleasant surprises."
Yahoo
6 days ago
- Yahoo
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the 24-month DOR of 72.2% (95% CI 64.1%, 78.8%) by Kaplan-Meier estimate in patients who achieved CR at three months from the Phase 3 ENVISION trial of ZUSDURI™ (mitomycin) for intravesical solution, a treatment for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The median follow-up time after a three-month CR in this analysis was 23.7 months. The median DOR has not been reached. 'This latest update from the pivotal ENVISION trial of ZUSDURI showed that, among patients who achieved a complete response at three months, the probability of remaining event-free 24 months after CR was 72.2%,' said Sandip Prasad, M.D., Director of Genitourinary Surgical Oncology and Vice Chair of Urology at Morristown Medical Center/Atlantic Health System, NJ, and Principal Investigator of the ENVISION trial. 'Among patients who achieved a complete response, the event rate over time has remained stable. This DOR result highlights the sustained efficacy of the therapy and reinforces its potential as a durable treatment option. For the first time, adult patients with recurrent LG-IR-NMIBC have an FDA-approved therapy. This marks a potentially transformative step forward in how we manage this chronic, highly recurrent, and disruptive cancer. ZUSDURI is a new, outpatient treatment option for patients that can help provide a clinically meaningful recurrence-free interval, which is compelling given the highly recurrent nature of LG-IR-NMIBC.' The existing standard of care for LG-IR-NMIBC is a surgical procedure typically conducted under general anesthesia called transurethral resection of bladder tumor (TURBT). Repeated TURBT procedures can impact patients' physical health and quality of life and can even be associated with an increased risk in mortality. Due to high recurrence rates, LG-IR-NMIBC patients, who are typically elderly with comorbidities, will likely need multiple TURBTs under general anesthesia over the course of their lifetime. An estimated 59,000 patients with LG-IR-NMIBC recur annually. According to Mark Schoenberg, M.D., Chief Medical Officer, UroGen, 'The 24-month duration of response data from the ENVISION trial underscore the transformative potential of ZUSDURI (formerly known as UGN-102) for adult patients with recurrent LG-IR-NMIBC. This is a population that has long endured a cycle of recurrence and repeat surgeries, a burden that weighs heavily, particularly on older adults. With ZUSDURI now approved, we have a new treatment option that can help deliver durable complete responses and meaningfully extend event-free intervals. This represents a major advance in the way we care for these patients.' The most common (≥ 10%) adverse reactions (ARs), including laboratory abnormalities, that occurred in patients were dysuria, increased potassium, increased creatinine, decreased hemoglobin, increased eosinophils, increased aspartate aminotransferase, increased alanine aminotransferase, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria. ARs were mainly mild to moderate. Serious ARs occurred in 12% of patients, including urinary retention (0.8%) and urethral stenosis (0.4%). About ZUSDURI ZUSDURI (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, approved for the treatment of adults with recurrent LG-IR-NMIBC. Utilizing UroGen's proprietary RTGel® technology (a sustained release, hydrogel-based formulation), ZUSDURI is delivered directly into the bladder by a trained healthcare professional using a urinary catheter in an outpatient setting, thereby enabling the treatment of tumors by non-surgical means. About Non-Muscle Invasive Bladder Cancer (NMIBC) LG-IR-NMIBC affects around 82,000 people in the U.S. every year and of those, an estimated 59,000 are recurrent. Bladder cancer primarily affects older populations with increased risk of comorbidities, with the median age of diagnosis being 73 years. Guideline recommendations for the management of NMIBC include TURBT as the standard of care. Up to 70 percent of NMIBC patients experience at least one recurrence, and LG-IR-NMIBC patients are even more likely to recur and face repeated TURBT procedures. Learn more about non-muscle invasive bladder cancer at About ENVISIONThe Phase 3 ENVISION trial is a single-arm, multinational, multicenter pivotal study evaluating the efficacy and safety of ZUSDURI (mitomycin) for intravesical solution as a chemoablative therapy in adult patients with recurrent LG-IR-NMIBC. The Phase 3 ENVISION trial completed target enrollment with 240 patients across 56 sites. Study participants received six once-weekly intravesical instillations of ZUSDURI. The primary endpoint evaluated the CR rate at three months after the first instillation, and the key secondary endpoint evaluates durability over time in patients who achieved a CR at the three-month assessment. Learn more about the Phase 3 ENVISION trial at (NCT05243550). About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and our second product, ZUSDURI (mitomycin) for intravesical solution for adult patients with recurrent LG-IR-NMIBC, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit to learn more or follow us on X (Twitter), @UroGenPharma. IMPORTANT SAFETY INFORMATIONAPPROVED USE FOR ZUSDURI ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after previously receiving bladder surgery to remove tumor that did not work or is no longer working. IMPORTANT SAFETY INFORMATION You should not receive ZUSDURI if you have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI. Before receiving ZUSDURI, tell your healthcare provider about all of your medical conditions, including if you: have kidney problems are pregnant or plan to become pregnant. ZUSDURI can harm your unborn baby. You should not become pregnant during treatment with ZUSDURI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZUSDURI. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with ZUSDURI and for 6 months after the last dose. Males being treated with ZUSDURI: You should use effective birth control (contraception) during treatment with ZUSDURI and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ZUSDURI passes into your breast milk. Do not breastfeed during treatment with ZUSDURI and for 1 week after the last dose. How will I receive ZUSDURI? You will receive your ZUSDURI dose from your healthcare provider 1 time a week for 6 weeks into your bladder through a tube called a urinary catheter. It is important that you receive all 6 doses of ZUSDURI according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. During treatment with ZUSDURI, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving ZUSDURI: ZUSDURI may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 24 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed separately from other clothing. The most common side effects of ZUSDURI include: increased blood creatinine levels, increased blood potassium levels, trouble with urination, decreased red blood cell counts, increase in certain blood liver tests, increased or decreased white blood cell counts, urinary tract infection, and blood in your urine. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436. Please see ZUSDURI Full Prescribing Information, including the Patient Information, for additional information. ZUSDURI™ is a trademark and UroGen® is a registered trademark of UroGen Pharma, Ltd. Copyright©2025 UroGen Pharma, Inc. All rights reserved. Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential benefits of ZUSDURI, including as an outpatient treatment option, its potential to provide durable CRs and clinically meaningful recurrence-free intervals and as a compelling alternative to TURBT given the high recurrence rates of LG-IR-NMIBC; the estimated annual U.S. patient population and demographics for LG-IR-NMIBC; the potential of UroGen's proprietary RTGel technology to improve therapeutic profiles of existing drugs other than mitomycin; and UroGen's sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as 'can,' 'estimate,' 'likely,' 'may,' 'potential,' 'will' or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: clinical results may not be indicative of results that may be observed in the future, including in larger populations; potential safety and other complications related to UroGen's products; the ability to maintain regulatory approval; complications associated with commercialization activities; labeling limitations; competition in UroGen's industry; the scope, progress and expansion of developing and commercializing UroGen's products and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen's ability to attract or retain key management, members of the board of directors and other personnel; UroGen's RTGel technology and ZUSDURI may not perform as expected; UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology; and the impacts of general macroeconomic and geopolitical conditions on UroGen's business and financial position. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 12, 2025, the events and circumstances discussed in such forward-looking statements may not occur, and UroGen's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release. INVESTOR CONTACT:Vincent PerroneSenior Director, Investor ext. 1093 MEDIA CONTACT:Cindy RomanoDirector, Corporate ext. 1083Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data